Guidance for Good Practice in Cervical Screening
4th Edition
Acknowledgements

Editorial Team:

**Jill Fozzard**
North East Cervical Screening Training Facilitator

**Lesley Greenwood**
North East Regional Cervical Screening Training Co-ordinator

July 2014
# Contents

## Section One

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Aims of Guidelines</td>
<td>5</td>
</tr>
<tr>
<td>Impact of Cervical Screening</td>
<td>5</td>
</tr>
<tr>
<td>The Cervical Screening Programme</td>
<td>5</td>
</tr>
<tr>
<td>Incidence of Cervical Cancer</td>
<td>6</td>
</tr>
<tr>
<td>Mortality</td>
<td>7</td>
</tr>
<tr>
<td>Coverage</td>
<td>8</td>
</tr>
<tr>
<td>Initiatives to Improve Coverage</td>
<td>9</td>
</tr>
</tbody>
</table>

## Section Two

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Papilloma Links</td>
<td>11</td>
</tr>
<tr>
<td>Risk Factors</td>
<td>12-13</td>
</tr>
</tbody>
</table>

## Section Three

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Taker Training</td>
<td>15</td>
</tr>
<tr>
<td>The Mentors Role</td>
<td>16</td>
</tr>
<tr>
<td>Training Supervision</td>
<td>17</td>
</tr>
<tr>
<td>E Learning</td>
<td>17</td>
</tr>
<tr>
<td>Taking a History</td>
<td>19</td>
</tr>
<tr>
<td>Preparation of the sample request form</td>
<td>20</td>
</tr>
<tr>
<td>Taking the Sample</td>
<td>21-23</td>
</tr>
</tbody>
</table>

## Section Four

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Result and Management Guidelines</td>
<td>25</td>
</tr>
<tr>
<td>Inadequate Samples</td>
<td>26</td>
</tr>
<tr>
<td>Women with Symptoms</td>
<td>27</td>
</tr>
<tr>
<td>Guidelines for cytological follow up after hysterectomy</td>
<td>28</td>
</tr>
</tbody>
</table>
Section Five

Practice / Clinic Responsibilities 29
Failsafe 29
Open Exeter 30
The Cervical Sample Taker Database 31
Role of Sample Taking Co-ordinator 31
Screening Intervals 32
Primary Service Agency and Practice Responsibilities for Programme Management 34-35
Organisational Indication for GP Practices 36-37

Section Six

Quality Assurance 39
Screening in Special Circumstances 40-41
Frequently Asked Questions 42-45
Useful Resources 46
Appendices 47
References 58
Introduction
This document has been produced by the Cervical Screening Training Department hosted by Newcastle upon Tyne Hospitals to provide standard guidance in cervical screening. It covers all elements of the NHS Cervical Screening Programme (NHSCSP), and is intended to support existing local documentation and the requirements of the GMS contract.

Aims of Guidelines
- To ensure that practice is in line with current standards and national policy.
- To outline the training requirements for sample takers in the NHSCSP.
- To clarify the roles of practices/clinics in cervical screening.
- To outline the requirements for audit.
- To offer clear advice to support consistent delivery of the NHSCSP.
- To address some of the issues and frequently asked questions that arise in a consultation.

Impact of Cervical Screening
Significant progress has been achieved since the Cervical Screening Programme was established in 1988. The cervical cancer mortality rate has fallen from 1,035 in 2000 to 742 in 2012 in women of all ages.¹ This fall is directly related to the NHS Cervical Screening Programme.

¹The Health and Social Care Information Centre. Statistical Bulletin 2012/13

For more information about cervical screening:
www.cancerscreening.nhs.uk/cervical

The Cervical Screening Programme
The aim of the NHS Cervical Screening Programme is to reduce the number of women who develop invasive cervical cancer (incidence) and the number of women who die from it (mortality). It does this by offering regular screening to all women at risk so that conditions which might otherwise develop into invasive cancer can be identified and treated.
**Incidence**

**What is the incidence of cervical cancer?**

In 2011, there were 2,511 new registrations of invasive cervical cancer in England.

Incidence and mortality rates in England have fallen considerably over the past 20 years. During this period, incidence rates almost halved (from 16.2 to 8.7 per 100,000 female population) and mortality rates reduced by almost two-thirds (from 6.4 to 2.1 per 100,000). Incidence fell sharply following the establishment of the Cervical Screening Programme in 1988, but this reduction has slowed in recent years. There is also strong evidence that both incidence and mortality are worse in patients living in the more deprived areas. (Profile of Cervical Cancer in England: Incidence, Mortality and Survival 2012).

Cervical screening is estimated to save approximately 4,500 lives per year in England and prevents up to 3,900 cases of cervical cancer per year in the UK. (www.cancerscreening.nhs.uk)

---

**Cervical Cancer (C53) Incidence rate (per 100,000)**

![Graph showing the incidence rate of cervical cancer from 1990 to 2010.](image)

Source: UK Cancer Information Service

*DSR: Directly Standardised Rate (1976 European) per 100,000 female population*
Mortality

How many women die from cervical cancer?

Death rates from cervical cancer have fallen below 800 per year in England. In 2012, 742 deaths from cervical cancer were registered in England.

Less than 7 per cent of cervical cancer deaths occur in women under 35.

Cervical cancer is the 16th most common cause of cancer deaths in women in the UK, accounting for around 2 per cent of all female cancers and it is the most common cancer in females under 35. Compared with 20 years ago, cervical cancer mortality is lower in all age groups.

In England, for women diagnosed between 2005 and 2007 the one year relative survival rate has increased from 82.2% to 86.2%.

Over the last 20 years, one-year relative survival has improved in all age groups, particularly for women aged 20-39, increasing from 93.0% in 1987-1989 to 96.6% in 2007-2009.

Source: UK Cancer Information Service
Coverage

Coverage is defined as the percentage of women in a population eligible for screening at a given point in time who were screened adequately within a specific period. The eligible population is women aged between 25 - 64 years with a cervix.

80% coverage is required for the NHSCSP to be effective. However, the information that is required to fulfil the criteria for the Quality Outcomes Framework (QOF) differs, see Section 5.

11 points are given for the percentage of patients aged from 25 – 64 years whose notes record that a cervical sample has been performed in the preceding 60 months. The standard is between 40 – 80%. Women who have been exception reported should be removed from this denominator. If a woman is exception reported, she is still eligible for screening and every effort should be made to encourage these women to be screened.

Of eligible women in England, (aged 25-64) at 31st March 2013, 78.3% were recorded as being tested within 5 years of their last adequate test. This compares to 78.6% in 2012. Coverage has been falling over the last ten years and this is the third consecutive year it has remained below 80%. The fall in coverage in 2011-12 is also apparent in the different age groups, for those aged 25 to 49 (who are invited every 3 years), coverage at 31st March 2013 was 71.5% compared with 73.5% in 2012. Among women in the older age range, 50 – 64 years (who are invited every 5 years), coverage at 31st March 2013 fell to 77.5% from 77.8% the previous year.
**Initiatives to Improve Coverage**

The National Institute for Health Research (NIHR) Health Technology Assessment Programme has commissioned a study to investigate ways of improving screening uptake of women when they are invited for the first time.

It will involve over 200 practices in Greater Manchester and 40 in Aberdeenshire and take four years to complete. The trial will test a range of interventions including a pre-invitation leaflet designed specifically for young women, offer internet booking opportunities, the benefits of self sampling and the use of nurse navigators.

There are a number of ways to encourage women to attend for regular cervical screening, which will help improve coverage rates. Listed here are some initiatives which have been shown to have a positive effect on coverage rates:

- Prior notification lists (PNLs) must be checked carefully to ensure all ‘ghost’ patients are removed and addresses are correct.
- It is recognised that women often give low priority to their own health needs and may need regular encouragement to attend for screening and advice.
- Use leaflets and information in appropriate languages. Many women are misinformed about various aspects of the tests.
- Consider if clinic times are appropriate. Offer regular evening and weekend clinics and take into account community events, which may be barriers to attendance (e.g. Friday prayers for Muslims, collection of children from school, etc).
- Provide information on alternative clinics where women can attend for screening if more appropriate times are available.
- Information should also advertise the benefits of attending for regular screening. Ensure patients are aware that the test can be done by a female doctor or nurse.
- Ensure that the service is culturally sensitive and that a female staff member is available and trained to offer information and guidance where language barriers exist.
- Ensure that the sample taking environment is appropriately equipped and offers complete privacy.
- Highlight medical records and insert computer prompts for all women who fail to attend.

Details of publications and leaflets are available on the NHS Cancer Screening Programmes website: [www.cancerscreening.nhs.uk](http://www.cancerscreening.nhs.uk)
Above posters available from: [www.orderline.dh.gov.uk](http://www.orderline.dh.gov.uk)
• For non-attendees, ensure the issue is raised at the next appropriate visit and that the patient is fully informed of the benefits of regular screening.

• Ensure reception staff has access to appropriate up to date information so they are fully informed of any changes to the screening programme.

• The Primary Care Services Agency (PCSA) invites eligible women for cervical screening on behalf of GP practices. This is done on two occasions. A third invitation is then undertaken by the practice.

An example of a letter which can be sent to women to represent the third invitation is available on our website www.cervicalscreeningtraining.co.uk (See Appendix 1)

As mentioned previously the Screening Programme has commissioned projects to identify barriers to screening, particularly in younger women especially those aged between 25 to 34. As barriers are identified this information will be shared to implement change strategies.
Guidance for Good Practice

SECTION TWO

Human Papilloma Virus

Improving Outcomes: A Strategy for Cancer (DoH January 2011) aimed to deliver healthcare outcomes as good as anywhere in the world. It acknowledged that cancer screening remains an important way to detect cancer early, and in some cases, such as cervical screening, prevent cancers. A part of this strategy set out how Human Papilloma Virus (HPV) testing is incorporated into the NHSCSP with the aim of leading to a more patient centred service and major cost savings.

HPV Testing

HPV testing is designed to speed up the referral to colposcopy, avoid referral for those who do not need it, and allow treated women to proceed to a three year recall.

Women known to be high-risk HPV negative are very unlikely to have significant disease. They can thus be reassured and returned immediately to routine recall without the anxiety of repeat screening tests and possible referral to colposcopy.

Women receive information on HPV testing with their invitation letter for cervical screening.

It should be documented on the request form that the woman is aware that the sample may be tested for the presence of HPV. The HPV test is not optional. It is an integral part of the screening programme on offer to women. It is then up to the woman to decide whether to participate or not on that basis. In other words, if the woman declines for the sample to be tested for HPV then she should not have a cervical sample taken.

How does HPV testing affect women?

Triage

Women whose cytology result is borderline or low grade will have a high-risk HPV test performed on their cytology sample. If it is positive they are referred to colposcopy. If it is negative they are returned to routine three of five year recall, depending on their age.

Women whose cytology test shows high grade dyskaryosis (moderate, severe dyskaryosis or worse) will not have an HPV test. They are referred to colposcopy.

Women whose cytology test result is negative will not have an HPV test.
Human Papilloma Virus (HPV)

There are about 140 strains of HPV, 40 of which infect the anogenital tract.

Certain strains are known to be high risk. HPV 16 and 18 are estimated to account for 70% of high grade cervical intraepithelial neoplasia (CIN) and cervical cancer. Strains 31, 33, 35, 52, 56 and rarely 39 and 45 are thought to account for the rest.

Persistent infection by high risk HPV is the most important causal factor for the development of cervical neoplasia.

Low-risk strains produce low-grade CIN lesions which tend to regress and usually do not progress. For example, HPV 6 and 11 are associated with genital warts and are unlikely to be associated with cervical cancer.

Test of cure

All women who have been treated* for CIN have a cytology test six months after their treatment. If cytology is normal or low grade dyskaryosis, a high-risk HPV test will be performed. Women who are high-risk HPV negative will return to routine three year recall. Women who are high-risk HPV positive or have high grade dyskaryosis will be referred back to colposcopy.

*Treatment is categorized as excision, for example, large loop excision of the transformation zone (LLETZ), laser or cryotherapy. A punch biopsy is not classified as treatment.

Cervical glandular intraepithelial neoplasia (CGIN) results are included in HPV testing.

For more information go to www.cancerscreening.nhs.uk

HPV Risk Factors

The majority of sexually active women will come into contact with high-risk HPV types at some time in their life. In most women, their body’s own immune system will get rid of the infection without them ever knowing it was there. Only a minority of women who have persistent infection by high-risk HPV sub-types will develop cervical abnormalities (CIN), which could develop into cervical cancer if left untreated.

Epidemiological studies investigating risk factors for HPV infection have shown clearly and consistently that the key determinants among women are the number of sexual partners, the age at which sexual intercourse was initiated and the likelihood that at least one of her sexual partners was an HPV carrier.²

Women with many sexual partners, or whose partners have had many partners, are more at risk of developing cervical cancer.
cancer. This is because their behaviour is more likely to expose them to HPV. However, a woman with only one partner could contract HPV if that partner has previously been in contact with the virus.

Using a condom offers only very limited protection from transmission of HPV. Women who are immunosuppressed (for example, those who are taking immunosuppressive drugs following an organ transplant or women who are HIV positive) may be at increased risk of developing cervical cancer.

Women who smoke increase their risk of developing cervical cancer. This may be because smoking is associated with high-risk health behaviours, or because it suppresses the immune system allowing the persistence of high risk HPV infection. Stopping smoking appears to help clinical abnormalities return to normal.

Long term use of oral contraceptives increases the risk of developing cervical cancer but the benefits of taking oral contraceptives far outweigh the risks for the majority of women.

Women with a late first pregnancy have a lower risk of developing cervical cancer than those with an early pregnancy. The risk rises with the number of pregnancies.

2NHSCSP The Aetiology of Cervical Cancer. Publication No. 22

Cervical screening prevents around 75% of cervical cancers in women who attend for regular screening. It is one of the best defences against cervical cancer. Many of those who develop it have never been screened.
The resource pack for sample taker training represents best practice for all sample takers and is available at www.cancerscreening.nhs.uk: see NHSCSP Publication No 23: Taking Samples for Cervical Screening. It is designed to be used for all sample takers in all settings where cervical samples are taken as part of the NHS Cervical Screening Programme (NHSCSP). The resource pack enables trainers to offer a common core of learning to all sample takers to ensure consistency and provide learning to a minimum recognised standard across the NHSCSP.

Health Care Assistants do not meet the criteria to be trained for taking cervical samples. (www.skillsforhealth.org.uk)

Organisation of training
The Regional Cervical Screening Training scheme, which has been in operation since 2000, is responsible for providing update training to all nurses who are sample takers. (A database is held of all the Practice Nurses who take cervical samples in the North East Region).

Update study days are provided in a variety of venues. These are advertised by sending flyers to all the relevant practices and clinics within the defined area. A list of scheduled Updates can be viewed on the Cervical Screening Training website www.cervicalscreentraining.co.uk

A Certificate level course is delivered by Cervical Screening Training.

Training for sample takers is in two parts; a theoretical course followed by a period of practical training which should take place in the practice or clinic where the trainee is based. Each student will be allocated a Cervical Screening Mentor (CSM) for the duration of the clinical practice and asked to identify a Professional Support within their workplace to provide support during the unsupervised clinical practice. Each trainee keeps a record of their training in a portfolio which is submitted as evidence of learning.

Further information is available on our website.

Theoretical course
Content includes:
• The NHS Cervical Screening Programme.
• The background to cervical screening.
• Organisation of the NHS Cervical Screening Programme.
• Equality of access to cervical screening.
• Understanding the test results.
• Anatomy and physiology of the pelvic organs.
• Practical aspects of taking cervical samples.
The Cervical Screening Mentors Role

The CSM facilitate and support good practice in relation to the practical aspects of cervical sample taking.

They are the mentor for new nurse sample takers and assist with the development and delivery of the update training programme for established sample takers.

The CSMs have good teaching and communication skills. They undertake regular update training and maintain awareness of developments in the Cervical Screening Programme.

They must be practising sample takers who are able to demonstrate continuing competence in taking samples for cervical screening with particular reference to:

- Transformation zone sampling.
- Technique.
- Equipment and sample preparation.
- Audit of results including adequacy rates & TZ sampling.
- Demonstrate good communication skills.
- Maintain awareness of developments in the Cervical Screening Programme.

Criteria for CSM:

- Registered General Nurse with 3 years recent experience, working as a Practice Nurse/Community Nurse.
- Undergone a recognised course for sample takers and have 2 years minimum experience in cervical screening in General Practice or contraception and sexual health setting.
- Demonstrate evidence of teaching ability, an understanding of the dynamics of working in Primary Care.

The CSMs are accountable to the North East Regional Cervical Screening Training Co-ordinator.
Training Supervision

**Practical training**
For the first practical session/s, the trainee will be accompanied by the CSM and will:

- Identify personal training needs in discussion with the CSM.
- Observe at least two samples being taken by the CSM.
- Take a minimum of five samples under supervision of the CSM.

The CSM and trainee should then decide whether the student may proceed without further direct supervision. Subsequently the trainee will take and document 20 unsupervised samples with access to a nominated Professional Support. The student will visit the Cytology laboratory, and the Colposcopy clinic, documenting and reflecting on the visits in their portfolio. The trainee should also write three reflective pieces of work related to their practice.

*The GMS contract identifies the importance of training in Cervical Cytology Sampling. Refer to CS001 indicator.*

**Clinical assessment**
Both CSM and trainee are expected to maintain regular contact, including contact midway and discuss progress towards meeting identified training needs and any problems. They then meet for an evaluation and clinical assessment. The trainee must have completed 20 samples before the assessment can be undertaken. All training should be completed within a nine month period.

To ensure continued competence in accordance with their professional codes of conduct, sample takers should conduct continuous self-evaluation. They should audit and reflect on their results compared with the rates reported by the local laboratory. They should maintain this in the form of a log book or spread sheet.

This information is available on the Cervical Sample Taker Database (CSTD), see Section 5.

**Update training**
Sample takers should undertake a minimum of one half day’s update training every three years. Update training should address the following issues:

- Current developments in the Cervical Screening Programme nationally and locally.
- Recent literature relevant to sample taking, sampling devices and women’s needs.
- Changes to local screening policies and procedures.
- Personal learning needs.

**E Learning**
An e-learning course is available for sample takers. It forms part of the three year update requirements and helps to maintain and improve knowledge of the cervical screening programme.

The e-learning can be accessed from [www.neyhqarc.nhs.uk/cervicalscreening](http://www.neyhqarc.nhs.uk/cervicalscreening)
Q1. Is the e-learning mandatory?
No, however it is recommended that this training package is undertaken to supplement the 3 year update training for nurses. Others wishing to undertake the e-learning are welcome to do so. If individuals feel they do not need to improve/reinforce their knowledge first they can do the assessment component only, which will decrease the time required for the module.

The CSTD devised by the Quality Assurance Reference Centre (QARC) enables screening co-ordinators and QARC to see an individual’s cervical training record and highlight cases where the e-learning has not been completed.

If a sample taker does not complete the e-learning, it would be their professional risk and the Practice’s responsibility as their employer. The practice and individual sample taker would need to be able to assure themselves that should they be the subject of investigation, through an incident/invasive cancer audit, staff were adequately trained.

Q2. How long will it take to complete the e-learning?
The course takes around 2 hours 45 minutes plus another 15 minutes for the assessment. However, if you already have the relevant knowledge you can go straight to the assessment.

Q3. Can the e-learning be used instead of undertaking initial training with a competency assessment?
No. The e-learning has been designed as a refresher for the theoretical aspect of cervical screening and is not a substitute for an initial training course with a competency assessment.
Taking a History

Obtain and record relevant details of:

- Cytology history – any abnormal cytology results, if so when, where, result, treatment, follow up. A woman’s cytology history is available from Open Exeter. Access to software system is available through an application from the Screening Office.
- Contraception.
- Abnormal Bleeding: - post coital bleeding - inter menstrual bleeding - post menopausal bleeding.
- If YES to any of above consider referral to gynaecologist/GUM - consider swabs if appropriate.
- Unusual vaginal discharge. Take swabs, consider postponing cervical sample until diagnosis & treatment completed.
- Ensure woman has received the Cervical Screening leaflet.

The following factors do not precipitate additional screening outside of normal call and recall:

- Taking or starting to take oral contraception.
- Insertion of an IUCD/IUS. Taking or starting to take HRT.
- Presence of genital warts. Presence of vaginal discharge.
- Presence of infection.
- Women who have had many sexual partners.
- Women who are heavy cigarette smokers.
- Family history of cervical cancer.

You should not take a sample in the following circumstances:

- During menstruation.
- Less than 12 weeks post-natal.
- Less than 12 weeks following a termination of pregnancy or miscarriage.

Women with symptoms or abnormal bleeding should be referred for further investigation. The screening test could offer false reassurance.

The screening test is not a diagnostic tool.
Cytology Request

There are two ways to request a cervical cytology sample.

**Handwritten sample request form (HMR101)**
- Full name, address and postcode
- Any previous names
- Date of birth
- NHS Number
- Name and address of GP and/or Clinic
- Sample taker code
- Date of LMP
- Date of last smear
- Hormones/IUS/IUD
- Any relevant history including previous abnormal cytology, histology, abnormal bleeding, abnormal appearance of the cervix.
- Complete form with black ballpoint pen.

**ICE (Integrated Computer Environment)**
ICE requesting provides a web based service that enables cytology requests to be made from clinics and GP surgeries. The system employs ‘rules’ to ensure only appropriate requests are made and full information is available to the laboratory. Customised request forms for both primary and secondary care, allows the use of labels printers, pre-labelled sheets and plain A4/5 if required.

**Labelling the vial**
- Name
- NHS number
- Date of birth
- Date taken

Please remember to check the expiry date of the vial. The HPV test may be invalid if the vial has expired; the shelf life is 3 years.

See [www.cancerscreening.nhs.uk](http://www.cancerscreening.nhs.uk) for guidance on HMR101 form filling.
Taking the Sample

The clinical environment:
- Private and relaxed
- Well lit
- Screened area for privacy
- Trolley or work surface next to the couch
- Area for hand washing and drying
- Clinical waste/bin nearby
- Lockable door if patient gives consent
- 20 minute appointment

Equipment:
- An examination couch
- A good light source
- Range of different sized speculae
- Disposable gloves
- Lubricant, single use sachets
- Disposable modesty sheet
- SurePath™ LBC Kit, which includes: 25 Cervex Brushes®, vials and labels, HMR101
- Tissues & panty liners
- ICE forms

Explaining the process:
You should explain to the woman the purpose of cervical screening and what will happen at each step of the procedure. Ensure that women have received the “Cervical Screening” leaflet and understands the procedure. Every woman should know:

- The purpose of cervical screening and its limitations.
- The likelihood of a normal test result (about 93% of adequate tests).
- The meaning of a normal test result (low risk not no risk).
- The likelihood of an inadequate test.
- The meaning of being recalled following an abnormal test result.
- When and how test results will be made available.
- The importance of the woman always reporting any abnormal bleeding or discharge to her doctor.
- Obtain consent regarding HPV testing.

Explain clearly to the woman what you are going to do during the procedure and what to expect. Women who are having a test for the first time may need a more detailed explanation, including an explanation of the speculum and the sampling device. Women need to know that they will have to remove their underwear and that the speculum will be inserted into their vagina. All women should be offered a chaperone irrespective of the sex of the sample taker.
Taking the Sample

Using the Cervex Brush, insert the central bristles of the brush into the endocervical canal so that the shorter, outer bristles splay out over the ectocervix. Applying pencil pressure, rotate the broom through **FIVE** complete 360° rotations. In order to ensure good contact with the ectocervix, the plastic bristles of the Cervex Brush are bevelled for **CLOCKWISE** rotation only.

A good sample will only be achieved with correct use of the Cervex Brush.

**Using an endocervical (EndoCervex Brush®) as well as a Cervex Brush®**

- On rare occasions when there is difficulty in inserting the Cervex Brush into the os i.e. if the os is narrow or stenosed.
- The woman is being followed up for a previously treated endocervical glandular abnormality.

You should take the EndoCervex Brush® sample after the Cervex Brush sample.

Insert the brush gently into the os with the lower bristles remaining visible and rotate slowly between half and a whole turn.

Both samples should be placed in the same vial. Details of use of an additional sampler must be recorded on request form.

**Immediately fix the sample For Sure Path™**

- Remove the head of the brush from the stem and place into the vial of fixative.
- Remove gloves
- Screw the lid on and shake gently.

*It is essential that the sample is placed in the vial at once in order to achieve immediate fixation. Do this before you remove the speculum.*
Taking the Sample

**Ending the consultation**

- Allow the woman to dress in private.
- Complete the form with any further clinical details.
- Ensure that the woman understands how and when she will receive her result.
- Give woman written information on results and possibility of Direct Referral.
- If the woman requires an interpreter, ensure that this is documented on the cytology request. In the event that should this be required it can be arranged for when the woman attends colposcopy.
- Ensure that the woman understands that if she has any abnormal bleeding or discharge in the future she must see her GP.
- Complete log book with details of sample taken.
- To avoid delay, ensure sample is sent promptly to the cytology laboratory via the appropriate transport system.

**Documentation**

The consultation should be formally documented in the patient’s records.

The following points should be noted:

- The cervix was fully visualized and the squamo-columnar junction was sampled with five complete 360° clockwise rotations.
- If a vault sample is taken this should be clearly specified.
- Date sample taken and by whom.
- Clinical details – unusual appearances.
- Chaperone offered/declined
- Details of swabs if taken
- Details of additional sampler if used
- Consent for HPV testing
theory  practice  update
## Routine Reports and Action

<table>
<thead>
<tr>
<th>Sample Result</th>
<th>Recall Interval/Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>Routine Recall 36 or 60 months, depending on age</td>
</tr>
<tr>
<td>Unsatisfactory/Inadequate</td>
<td>Repeat at 3 months. Reason for inadequate will be given by laboratory. Direct Referral to colposcopy may be indicated if 3 inadequate samples.</td>
</tr>
<tr>
<td>Borderline Squamous Low Grade (mild)</td>
<td>See HPV Triage &amp; Test of Cure</td>
</tr>
<tr>
<td><strong>High Grade dyskaryosis (Moderate/Severe Dyskaryosis)</strong></td>
<td>Direct Referral to colposcopy</td>
</tr>
<tr>
<td><strong>Severe Dyskaryosis? Glandular Neoplasia</strong></td>
<td></td>
</tr>
</tbody>
</table>

As per NHSCSP Publication No. 20 Colposcopy & Programme Management 2010
Inadequate Samples

Less than 1-2% of samples are reported as inadequate. Reasons for sample inadequacy include:

- Poor cellular sample (scanty)
- Sample consisting largely of blood, neutrophils or polymorphs with few squamous cells.
- Sample showing marked cytolysis where few intact squamous cells remain.
- Samples lacking endocervical cells in follow up of treated endocervical dyskaryosis.
- No brush head in vial.
- Fluid spilt/leaked from vial.

Helpful tips to reduce inadequate rates

Apply sufficient pencil pressure to splay lateral bristles of brush on surface of endocervix.
Perform five complete 360° rotations.
Rotate clockwise.
For LBC technology, immediate fixation is required.
Do not take a sample if there is abnormal vaginal discharge; unless the woman is a poor attender, in which case always take cervical sample first before swabs.
In women who are menopausal consider topical oestrogen.

Cervical Screening is a test for precancer NOT infections. These are incidental findings. Any abnormal discharge should be investigated according to protocols.

A breakdown of the information on cervical samples will be provided by the Cervical Sample Taker Database, see Section 5. However it is the sample takers responsibility to audit their own practice. This should include:

Total of samples taken by practice and by individual sample takers.
- Overall inadequate rate for practice (number and percentage).
- Inadequate rate for individual sample taker (number of cases and percentage).
- Breakdown of reasons for sample inadequacy.
- Transformation Zone pick up.

Negative results, with organisms identified

Guidance from the National Office of Cancer Screening Programmes and the National Screening Committee, states that laboratories will not report the presence of organisms to the screening office but will include them on the cytology report to the sample taker.

Incidental findings:-

- Actinomyces - like organisms are identified. This organism is usually associated with the presence of an IUD/IUS. If the patient was symptomatic at the time the sample was taken, please refer to your local gynaecological or GUM/Sexual Health Service for advice on management. If asymptomatic, advise return for clinical examination if symptoms develop.
- Endometrial Cells - see NHS CSP publication, 3rd edition.
- Candida - the reporting of candida on the cytology report does not require the woman to have treatment if she is asymptomatic.
- Trichomonas - like Organisms; this does not indicate a definitive diagnosis. In order to manage the woman appropriately further investigations may be required. The laboratory report will state “Please refer to your GUM/Sexual Health Service for confirmation of diagnosis and advise on treatment.”
Women presenting with symptoms of cervical cancer, i.e. postcoital bleeding in women over 40 years, intermenstrual bleeding and persistent vaginal discharge, should be referred for gynaecological examination and onward referral for colposcopy if cancer is suspected.

Contact bleeding at the time of cervical sampling may often occur and is not an indication for referral for colposcopy in the absence of other symptoms or an abnormal cytology result.

Clinical practice guidance for the assessment of young women aged 20-24 with abnormal bleeding

The number of women aged 20-24 years who develop cervical cancer is generally fewer than 50 cases per year and this will fall over the next 10 years as a consequence of the national HPV vaccination programme.

By contrast abnormal vaginal bleeding is relatively common in this age group. It has been estimated from a general practice dataset in Scotland that postcoital bleeding is reported by around 1 in 600 women aged 20-24 per year. Intermenstrual bleeding is more common than this and it may be that 0.5-1% of women in this age present with abnormal vaginal bleeding each year. There are around 1.5m women aged 20-24 in England and it could, therefore, be estimated that 7,500 – 15,000 women per year will report abnormal vaginal bleeding. In practice the number could be larger than this.

In Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding, (see Appendix 3) the Department of Health advises that the cardinal symptom of cervical cancer in this age group is postcoital bleeding, but persistent intermenstrual bleeding (which is more common) also requires attention.

The critical intervention in the diagnosis of cervical cancer is an immediate speculum examination to enable a clear view of the cervix. Following a relevant history, it is therefore necessary for women who present with postcoital bleeding or persistent intermenstrual bleeding to be offered a speculum examination either in primary care or at a GUM clinic.

This could be performed by a practice nurse experienced in cervical screening. If the cervix looks abnormal and suspicious, which will be the case in a very small proportion of cases, the correct action is urgent referral to colposcopy.

The guidance can be obtained from http://www.cancerscreening.nhs.uk/cervical/ Colposcopy Direct Referral

The laboratory will refer women directly to Colposcopy if indicated. The woman must be given clear instructions on how the appointment may be easily changed if it is not convenient.
Follow up after Vault Cytology

Vault cytology is no longer part of the NHS Cervical Screening Programme. The NHAIS (Exeter) System should neither recall women for vault cytology nor record any such results.

The Colposcopy QA Committee recommends that the responsibility for patient follow up lies initially with the gynaecologist and later with the GP after discharge to primary care. It is important to remember that women who undergo a subtotal hysterectomy will still have their cervix in situ and so must remain within the National Screening Programme. These women will still require to be followed up as per guidelines in NHSCSP Publication No 20: Colposcopy and Programme Management (2010)

Guidelines for cytological follow up after hysterectomy

This summary is based on NHSCSP Publication No 20: Colposcopy and Programme Management (2010) and is supplemented by expert opinion regarding the sample taker and technique of vault sampling. (See Appendix 4)

The recommendations are as follows:

1. Women on routine recall for at least 10 years prior to hysterectomy and no CIN in hysterectomy specimen: No vault cytology required.

2. Women with <10yrs routine recall and no CIN in hysterectomy specimen: A sample should be taken from the vaginal vault 6 months after hysterectomy and if negative no further cytology is necessary.

3. Women with completely excised CIN in hysterectomy specimen: A sample should be taken from the vaginal vault at 6 and 18 months after surgery with no further cytology if both are negative.

4. Women with incomplete or uncertain excision of CIN in hysterectomy specimen: Follow up should be conducted as if the cervix were still in situ i.e. for low grade disease at 6, 12 and 24 months after surgery (low risk follow up) and for high grade disease at 6 and 12 months followed by annual follow-up for at least the subsequent nine years (high risk follow up).

5. Women who have undergone radical hysterectomy for cervical cancer: In general, cytological follow-up is not recommended in the assessment of these women but decisions regarding this small group of patients should be determined by the gynaecological oncologist who carries out the procedure.

6. Women who have undergone radiotherapy for the treatment of a cervical cancer: Cervical or vaginal vault cytology should not be performed on women who have undergone radiotherapy as part of their treatment.

Guidance on performing a vault sample

When performing a vault sample the preparation, patient positioning and equipment required are exactly the same as for a cervical sample. The cytology request form should be completed with all relevant history including the reason for the hysterectomy. A full explanation should be given to the woman prior to commencing the procedure. The woman should be asked to adopt a comfortable position. The required speculum size should be selected and inserted in the same manner as when taking a cervical sample.

When the speculum is fully inserted and gently opened, the area of the vault can sometimes be identified as a scar line with residue tissue at either end. A Cervex Brush should be used to sweep over the entire area in a clockwise direction, making sure that this includes both of the corners of the vault. The Cervex Brush should then be placed immediately into the LBC vial. The speculum should then be removed and the clinical details completed on the cytology request form.


**Failsafe**

**All GPs (or other clinicians responsible for requesting tests) are responsible for:**

- Maintaining a register of tests taken.
- Ensuring that there is a system for notifying women of their test results in writing (this may be through the routine call and recall system administered by the PCSA).
- Ensuring that arrangements are made for women who fall outside the call and recall system (e.g. temporary residents, women not registered with a GP and women requesting ‘no correspondence’) to be given their test results, checking that a test result has been received from the laboratory for every sample taken.
- Acting on non-responder notifications for women who have not responded to an invitation for a routine test.
- Acting on non-responder notifications for women who have not responded to invitations for an early repeat test.
• Giving a woman her test result in person when urgent referral is required.
• Referring a woman for colposcopy if required.
• Acting on the non-responder notification from the colposcopy clinic for women who have not attended for colposcopy.

• Responding to failsafe enquiries from laboratories.
• Ensuring system in place for call & recall for vault cytology as per guidelines

Further information is available at: www.cancerscreening.nhs.uk see NHSCSP Publication No 21: Guidelines on Failsafe Actions for the Follow-Up of Cervical Cytology Reports.

Open Exeter
Open Exeter is a web-enabled viewer from the NHS Connecting for Health that gives agencies the opportunity to share information on the NHAIS (Exeter) database with their local GP practice and other NHS organisations.

The system holds details of women’s screening history i.e. details of all tests including the date, result and the recommendation made by the laboratory for recall interval. As there are links between all NHAIS systems, and copies of the screening history are electronically transferred between systems when a woman moves, this information is particularly useful for GP practices to view the screening history of newly registered patients.

The Prior Notification List (PNL) is one of the key documents in the call/recall programme. It is essential that the lists are completed each week to ensure that women are invited for screening at the appropriate time. To reduce the paperwork for GP practices the PNL can be made available via Open Exeter. Practices can then access the list, process and submit the response electronically. Once registered to complete the PNL on-line the practice will no longer receive the paper listing. Instead it will receive an e-mail advising that the PNL is available for completion.

Non Responder notifications are sent to practices if there is no record of a woman attending for a test after having been sent an invitation and reminder letter. These notifications which were previously sent on cards can be made available via Open Exeter. The vast majority of these notifications are for information only and will require no action from the practice, other than to click a button to acknowledge receipt. However, as with Prior Notifications, there is the facility for the GP practice to request that recall should be postponed or ceased.

The Open Exeter System can also be used to record details of HPV vaccinations to ensure the information is recorded against cervical screening records for the future. Once vaccination details have been recorded the information is stored on the NHAIS system and should the girl subsequently move to live in another area then details of vaccinations will be forwarded to the NHAIS system that serves that area.

All access to Open Exeter is very strictly controlled with only certain organisations having sufficient access to correctly identify patients registered at GP practices. For practices access is controlled so that only information relating to patients registered with that practice can be accessed. It is also recognised that even within a practice there are different access requirements and therefore all access is granted on an individual basis with the practice controlling which staff have access to the different information types.

If your practice is not registered please contact the North East Primary Care Services Agency (PCSA) on 0191 275 4200 and ask for the Open Exeter Data Controller. If your practice is already registered and you wish to register additional users your practice Primary Contact will need to approve the registration. The Primary Contact for the practice is usually the Practice Manager or one of the GPs. Your Primary Contact will advise you whether you will need to complete a Data User Certification form or whether registration can be done on-line.
The Cervical Sample Taker Database (CSTD)
A web based system provides a register of all sample takers and holds training and performance data which will allow quality to be monitored. Sample takers need to be registered on the system by either their practice based Sample Taking Co-ordinator (formerly known as Clinical Lead), see below for responsibilities, or Practice Manager in order to be allocated a unique sample taker code.

The web based system will also be able to provide practice profiles; for example, overall practice performance, performance broken down by sample taker and practice coverage rates. This system is being managed by the Quality Assurance Reference Centre based in Leeds, whose role it is to ensure quality and high standards in cancer screening throughout the North East, Yorkshire and The Humber. For more information see http://www.neyhqarc.nhs.uk/

Role of Sample Taking Co-ordinator
• Act as a link for the practice/department with the other professionals in the programme and advocate for all aspects of cervical screening.

• Ensure that the screening activity taking place at that location meets national and local guidance.

• Ensure that all sample takers operating at that location are adequately trained, and participate in regular updates.

• Produce and update local protocols. See example of Practice Protocol (Appendix 5).

• Disseminate information from the PCT and other relevant bodies to all sample takers at that location.

• Inform their employer and the PCT of any concerns from (or about) sample takers operating at that location.

• Support sample takers to:

• Comply with national guidance & quality standards.

• Undertake self-audit.

• Monitor attendance of sample takers at update training.

• Monitor sample taker performance data and act accordingly

• Monitor the performance of the practice with regards to the NHSCSP such as coverage and non-attendance.

• Ensuring processes are in place to respond to failsafe enquiries and that sample takers follow these.

• Register the sample takers at their location on the Cervical Sample Taker Database.

• Ensure the list of sample takers practicing at their location is kept up to date on the Cervical Sample Taker Database.

• Regularly access the Cervical Sample Taker Database as a performance monitoring tool.

• Ensure that the sample taking status of the sample takers at their location is up to date on the Cervical Sample Taker Database.

• Ensure that their personal details are up to date on the Cervical Sample Taker Database.
Screening Intervals

<table>
<thead>
<tr>
<th>Age Group (years)</th>
<th>Frequency of Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>24½</td>
<td>First invitation</td>
</tr>
<tr>
<td>25-49</td>
<td>3 yearly</td>
</tr>
<tr>
<td>50-64</td>
<td>5 yearly</td>
</tr>
<tr>
<td>65+</td>
<td>Only screen those who have not been screened since age 50 or those who have had recent abnormal tests</td>
</tr>
</tbody>
</table>

The administrative tasks associated with the call and recall of women within the NHS Cervical Screening Programme are undertaken by the Primary Care Services Agency.

These tasks include:
- Ensuring all eligible women aged 25-64 are included in the screening programme.
- Inviting all eligible women to attend for screening.
- Notifying women of their test result.
- Ensuring appropriate follow up/recall.

Call and Recall
NHSCSP Publication 18 provides a detailed Good Practice Guide for the administrative tasks associated with call and recall. Key points from that guide are detailed below.

Ensuring eligible women are included in the screening programme:
- Ensure all women are included in the programme by their 25th birthday.
- Ensure all women aged 25–64 and registering in the area for the first time are included in the programme.

Cervical Screening leaflets can be downloaded in PDF format, in several languages from the NHSCSP website: www.cancerscreening.nhs.uk

Available in several languages, large print, Braille and audio format.
Inviting Eligible Women:
- Send the NHSCSP leaflet Cervical Screening with all invitation and reminder letters.
- If invitation letters are returned ‘undelivered’ set recall status to ensure new letter produced on receipt of new address.

Recording and notifying test results:
- Return any results which fail system validation checks to the laboratory for clarification.
- Notify the woman’s GP if the result letter is returned ‘undelivered’ and set the call/recall system to ensure a new letter is produced on receipt of a new address.
- Send the result letter to the address given by the woman at the time of her test, unless records show she has moved since that date.

Ensuring appropriate follow up / recall:
- Send non-responder notifications to GP practices for any women who fail to respond to the two invitation letters.
- Send notification to GP practice for any newly registered women who are on early recall.
- Set the computer system to ensure screening histories for women who move to live in another area, are transferred on a daily basis.
## Summary of Primary Care Services Agency and Practice Responsibilities for Programme Management

<table>
<thead>
<tr>
<th>PCSA</th>
<th>PRACTICE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Call and Recall</strong></td>
<td></td>
</tr>
<tr>
<td>Ensure all women are included in the Programme.</td>
<td>Complete and return Prior Notification Lists (PNL). GP or PN to sign/authorise PNL if a woman is removed for any other reason than moved away.</td>
</tr>
<tr>
<td>Check with the GP Practice to ensure invitation is appropriate (Prior Notification Lists or e-PNL)</td>
<td>Ask Primary Care Services Agency to postpone invitation if appropriate:</td>
</tr>
<tr>
<td>Send a disclaimer letter to women who wish to withdraw from screening and are fully aware of what this involves.</td>
<td>• Sample not appropriate at time.</td>
</tr>
<tr>
<td></td>
<td>• Fully informed woman who declines current invitation.</td>
</tr>
<tr>
<td><strong>Invitation</strong></td>
<td></td>
</tr>
<tr>
<td>Send the woman an invitation 4-6 weeks before sample is due. This is 1st invitation letter.</td>
<td>Flag records for discussion when woman next attends the practice.</td>
</tr>
<tr>
<td>Send reminder letter 18 weeks later if the woman fails to respond to the invitation. This is 2nd invitation letter.</td>
<td>The practice can exception report the woman as she has been invited three times in preceding 12 month period.</td>
</tr>
<tr>
<td>Practice should send 3rd invitation letters to patients who have not attended.</td>
<td>Sending a 3rd invitation letter is a requirement as per GMS/PMS contract. (See Appendix 1)</td>
</tr>
<tr>
<td>12 weeks later send non-responder card to the practice if no result is received after 3 invitations. At this point the women is returned back into the system for appropriate months depending on the result of her last test. (At this point the practice can exception report the lady as she has been invited 3 times in the preceding 12 months).</td>
<td></td>
</tr>
<tr>
<td><strong>Sample Taking</strong></td>
<td></td>
</tr>
<tr>
<td>NHS England Area Teams are responsible for commissioning suitable and adequate cervical screening services.</td>
<td>Obtain informed consent in accordance with the Cervical Screening leaflet.</td>
</tr>
<tr>
<td></td>
<td>Agree with the woman how she will be informed of the result</td>
</tr>
<tr>
<td></td>
<td>Take cervical sample according to national guidance (see section 3).</td>
</tr>
<tr>
<td></td>
<td>Complete request form with accurate name, demographic and clinical details, sampler used, previous abnormalities, treatment &amp; HPV discussed with the woman.</td>
</tr>
<tr>
<td></td>
<td>Record sample taker code on request form.</td>
</tr>
<tr>
<td></td>
<td>Document the consultation.</td>
</tr>
<tr>
<td></td>
<td>Give woman information on results and possibility of Direct Referral.</td>
</tr>
<tr>
<td></td>
<td>Verify the sample labelling and send the sample on the same day to the laboratory.</td>
</tr>
</tbody>
</table>
### Summary of PCSA and Practice Responsibilities for Programme Management

<table>
<thead>
<tr>
<th>PCSA</th>
<th>PRACTICE</th>
</tr>
</thead>
</table>
| **Results** | • Always give the woman her test result in person if invasive. Ensure appropriate referral is made.  
• If urgent referral is required, the woman should be notified on a personal basis in a manner that is appropriate for her individual circumstances  
• Document result in medical records |
| Send the woman result letter (unless asked not to).  
Notify the sample taker/GP practice if for any reason the result cannot be sent. |  |
| **Managing Non-Attendees/Failsafe** | Fully inform the woman of implications of non-attendance, preferably face-to-face.  
Urgency depends on the situation:  
• Call/routine recall – flag record for discussion when the woman next attends practice.  
• Early repeat sample – flag record and ask the woman to attend practice.  
• Non-attendance at colposcopy – flag record and ask the woman to attend practice.  
• GP is responsible for ensuring colposcopy has taken place even if direct referral operating.  
• GP responds to laboratory failsafe enquiry. |
| Send non-responder card to practice if no result received after three invitations. (3rd invitation must be sent by practice). |  |
| **Ceasing Policy** | Ask PCSA to cease recall due to:  
• Age.  
• No cervix.  
• Radiotherapy for cervical cancer.  
• Other. In accordance with current NHSCSP guidelines. |
| Only cease women who fulfil criteria or who have asked in writing to be removed from the screening programme. Ensure that they have received sufficient accurate information to make an informed choice.  
Ensure the woman has been advised in writing of how she can be included in the programme at a future date should she change her mind.  
**For further information see:**  
Cervical Screening Call and Recall:  
Guide to Administrative Good Practice. NHS Cervical Screening Programme, 2004 (NHSCSP Publication No. 18)  
Withdrawing from the NHS Cervical Screening Programme: interim guidance, NHSCSP October 2009.  
Both are available at www.cancerscreening.nhs.uk/cervical | If a woman requests to withdraw from the Cervical Screening Programme, ensure she has sufficient, accurate information to make an informed choice, is capable of making and communicating that choice, and that she has expressed the desire to be ceased in writing.  
Women are required to provide written confirmation to the PCSA of their intention to be removed from the programme and must sign the appropriately worded Disclaimer Form/letter. |
Organisational Indicator for GP Practices

The following cervical screening indicators have been taken from the GMS Contract.

www.nhsemployers.org/Aboutus/Publications/Documents/qof

Public health domain - additional services

For contractors providing additional services the following indicators apply.

Please note exception reporting does not apply to those additional services indicators that do not have achievement thresholds.

Cervical screening (CS)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS001. The contractor has a protocol that is in line with national guidance agreed with the NHS CB for the management of cervical screening, which includes staff training, management of patient call/recall, exception reporting and the regular monitoring of inadequate sample rates</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>CS002. The percentage of women aged 25 or over who have not attained the age of 65 whose notes record that a cervical screening test has been performed in the preceding 5 years</td>
<td>11</td>
<td>45-80%</td>
</tr>
<tr>
<td>CS003. The contractor ensures there is a system for informing all women of the results of cervical screening tests</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>CS004. The contractor has a policy for auditing its cervical screening service and performs an audit of inadequate cervical screening tests in relation to individual sample-takers at least every 2 years</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

CS indicator 001

The contractor has a protocol that is in line with national guidance agreed with the NHS CB for the management of cervical screening, which includes staff training, management of patient call/recall, exception reporting and the regular monitoring of inadequate sample rates

CS 001.1 Rationale

If a robust system for the management of cervical screening is not in place then this is an area of great risk for general practice. The policy may have been drawn up outside the practice and is recommended to be in line with national guidance.

See guidance on exception reporting in section CS 002.1 contractor guidance.

The contractors protocol could be in the form of a written policy covering the issues outlined in the indicator wording.

CS 001.2 Reporting and verification

See indicator wording for requirement criteria.

The relevant practice staff are to be aware of the policy and the NHS CB may require that the contractor can demonstrate how the systems operate.
**CS indicator 002**

*The percentage of women aged 25 or over and who have not attained the age of 65 whose notes record that a cervical screening test has been performed in the preceding 5 years*

**CS 002.1 Rationale**

This indicator is designed to encourage and incentivise contractors to continue to achieve high levels of uptake in cervical screening.

The contractor may be required to provide evidence of the number of eligible women, aged 25 or over and under the age of 65, who have had a cervical screening test performed in the last five years/60 months.

This indicator differs from all the other additional service indicators in that a sliding scale will apply between 45 and 80 per cent, in a similar way to the clinical indicators.

Exception reporting (as detailed in the clinical domain) will apply and specifically includes women who have had a hysterectomy involving the complete removal of the cervix.

The exception reporting rules regarding criteria A require that three separate invitations are offered to the patient before that patient can be recorded as 'did not attend'. Therefore:

- In those areas where the first two invitations are sent via the central screening service, then contractors are responsible for offering the third invitation before exception reporting patients as DNA; or
- Where the central screening service sends out only one letter, then contractors are responsible for offering the second and third invitations before exception reporting patients as DNA.

The exception reporting criteria is not applicable to contractors that have opted to run their own call/recall system. These contractors will still be required to offer all three invitations directly in order to meet the DNA criteria. Copies of the letters sent by the contractor may be required for assessment purposes.

Women can choose to withdraw from the national screening programme. As the indicator requires that screening is delivered every five years, in order for a woman to be exception reported for this period, criteria G which requires that a discussion has taken place between the patient and the practitioner before ‘informed dissent’ can be recorded.

Women who withdraw from cervical screening call/recall will receive no further offers of screening from the central screening service.


**CS 002.2 Reporting and verification**

See indicator wording for requirement criteria.

The NHS CB may require that the contractor can provide a computer print-out showing the number of eligible women on the contractor list, the number exception reported and the number who have had a cervical screening test performed in the preceding five years. Contractors can exception report patients in the same way as the clinical indicators and the NHS CB may enquire how patients who are exception reported are identified and recorded.

**CS indicator 003**

*The contractor ensures there is a system for informing all women of the results of cervical screening tests*

**CS 003.1 Rationale**

It is generally accepted as good practice for all women who have had a cervical screening test performed to be actively informed of the result. The central screening service are responsible for informing women of the results in writing and the contractor ensures that all women have received the results.

**CS 003.2 Reporting and verification**

See indicator wording for requirement criteria.

The NHS CB may ask the practice team to explain how women are informed of the way they will obtain the result of their screening test and how queries from patients are managed.
CS indicator 004
The contractor has a policy for auditing its cervical screening service and performs an audit of inadequate cervical screening tests in relation to individual sample-takers at least every 2 years.

CS 004.1 Contractor guidance
In this audit the criteria, the results, corrective action, the results of the re-audit and a discussion of them needs to be presented. The standard or level of performance against which the criterion is judged would usually involve looking for sample-takers who are obvious outliers in relation to the reading laboratory’s average for inadequate samples.

CS 004.2 Written evidence
See indicator wording for requirement criteria.

The NHS CB may require that an audit of inadequate samples is recorded.

The NHS CB may also request a discussion takes place with sample-takers covering the audit and any educational needs which arose and how these were met.
Quality Assurance

The role of the Quality Assurance Reference Centre (QARC) is to monitor and maintain minimum standards of service, performance and quality across all elements of the Cervical Screening Programme and to promote and lead the continual pursuit of excellence in these areas.

The NHSCSP published National Quality Assurance Guidelines for the Cervical Screening Programme in 1996, and has a regional system of quality assurance which includes:

- A Quality Assurance Director for Cervical Screening.
- The identification of lead professionals to oversee co-ordination of audit in each area of professional activity in the Cervical Screening Programme.
- The review of the performance of the Screening Programme against National Quality Standards.
- Facilitate external quality assessment schemes.
- An administrative structure including a Quality Assurance Reference Centre to co-ordinate professional activity, statistical returns, and liaison with national activities.
- The development of training programmes within the region and support of training efforts in each laboratory and regional cytology training schools.
- Liaising with regional cancer registries to identify and audit cases of invasive cancer to evaluate the effectiveness of the Screening Programme.

What to do if there is suspicion of a critical incident affecting the programme

In the last 15 years or so there have been a number of widely publicised incidents in the Cervical Screening Programme. Most of these have involved problems with the reporting of samples by cervical cytology laboratories. However, there have been examples of problems with other areas of the programme, for example the quality of sample taking, reporting of results to sample takers, the transfer of results from laboratories and problems with the quality of colposcopy.

There are robust mechanisms in place should you suspect that an incident has, or may occur that could affect the programme. In the first instance, any suspicions should be directed to the Trust Clinical Governance Team and QARC who will investigate the matter.
Physical / Learning Disabilities

It should not be assumed that disabled women are sexually inactive and therefore do not require screening. Women should not be automatically excluded from the screening programme on the grounds of any physical or learning disability.

Disabled women have the same rights of access as all other women to the NHS Cervical Screening Programme. Wherever possible women with a disability should:

- Have access to information to enable them to make their own decisions about whether or not to accept an invitation to attend for cervical screening.
- Know what to expect when they attend for screening so that it is a positive experience.
- Understand the possible consequences of screening and of not having screening and the need to be aware of changes in their own bodies.

Comprehensive advice for sample takers and GPs is provided in the publication; Equal Access to Breast and Cervical Screening for Disabled Women NHS CANCER SCREENING SERIES NO 2.

There are some instances in which a woman with physical disabilities may find it difficult to achieve a position whereby the cervix can be fully seen and a cervical sample taken. Some difficulties may be overcome by:

- Offering a screening venue with equipment such as a hoist.
- Offering a longer screening appointment (there are some medical conditions whereby a woman will be able to comply with screening requirements given sufficient time).

If a cervical screening test is not technically possible at a screening appointment, the woman should still remain in the call and recall programme, as increased mobility at a future date may subsequently facilitate screening.

Learning disabilities alone are not a reason for not taking a cervical sample. Materials are available at: www.cancerscreening.nhs.uk to assist women with learning disabilities to make an informed choice about whether to participate in the programme or not.

For disabled women, as with other women, the issue of valid consent is crucial. The following points should be considered when assessing a woman’s capacity to consent to cervical screening:

1. Does the woman have a basic understanding of what cervical screening is, its purpose, and why she has been invited?
2. Does she understand that the test does not always find that something is abnormal?
3. Does she understand that an abnormal test result will mean having more tests?
4. Is she able to retain the information for long enough to make an effective decision?
5. Is she able to make a free choice (i.e. free from pressure from supporters or health professionals)?
Screening in Other Circumstances

**Women with a terminal illness**
Women in this situation should continue to be treated in the same way as women who do not have a terminal illness for as long as possible. This includes being invited for cervical screening as long as they are well enough. It is then the woman’s decision to attend or not. Women should be treated depending on their individual situation.

**Radiotherapy**
Women who have undergone radiotherapy treatment for cervical cancer should remain under the care of the Gynaecological Oncologist. Cervical samples are not appropriate as radiotherapy can produce changes which mimic dyskaryosis.

**Female Genital Mutilation**
Women who have been circumcised may have been exposed to high risk HPV and therefore remain at risk from cervical cancer. As such they should remain within the screening programme; however, taking a cervical sample should be handled sensitively and may not be possible in some cases. Every woman should be considered individually. In certain circumstances it might be appropriate to refer the woman to colposcopy.

**Pregnant/post natal women**
Avoid screening during pregnancy. It is not advisable to sample the cervix until 12 weeks post natal. Women who are being followed up from a previous abnormal may require screening. Seek advice from Colposcopy Department.

**Hysterectomy**
Women who have undergone total hysterectomy no longer require cervical screening. Women with a sub-total hysterectomy still have a cervix, and should therefore remain in the programme since they continue to be at risk.

**Male to female gender reassignment**
A person who has undergone a male to female sex change will not have a cervix and therefore is not eligible for cervical screening nor are they at risk.

**Female to Male gender reassignment**
See ‘Frequently Asked Questions’ page 44.

**Women who are immunosuppressed**
Women who are immunosuppressed may, depending on the causes of the immunosuppression, be at increased risk of developing cervical cancer. The following categories of women need more frequent screening and/or earlier referral for colposcopy:

- Women undergoing renal transplantation should have had cervical cytology within one year. If no history of CIN is present cytology screening should continue as per the national guidelines for non-immunosuppressed.
- Women newly diagnosed with HIV over 25 should have cervical cytology performed by, or in conjunction with, the medical team managing the HIV infection. Annual cytology should be performed with an initial colposcopy if resources permit.

Specialist clinicians should make arrangements with their local laboratory for the more frequent screening of these women as detailed above.

Further information is available at: www.cancerscreening.nhs.uk NHSCSP Publication No 20, Colposcopy and Programme Management

The following categories do not require more frequent screening:

- Women receiving long term cytotoxic drugs for rheumatological disorders.
- Women receiving cytotoxic chemotherapy for non-genital cancers.
- Women receiving long term steroids.
- Women receiving oestrogen antagonist such as tamoxifen.

*All such women should have cytological screening in accordance with National Guidelines.*
CERVICAL SCREENING TRAINING

Frequently Asked Questions

Q: Why are women under 25 and women over 65 not invited for screening?

Cervical cancer is rare in women under 20. However, infection with Human Papilloma Virus (HPV) which causes cervical cancer is very common in teenagers and women in their early 20s. Most of these infections will resolve spontaneously and do not need treatment. Screening of this age group may therefore do more harm than good.

The evidence suggests that screening can start at age 25. Lesions that are destined to progress will still be screen-detectable and those that would regress will no longer be a source of anxiety. Younger women will not have to undergo unnecessary investigations and treatments.

Any woman under 25 who is concerned about her risk of developing cervical cancer or her sexual health generally, should contact her GP or Genito-Urinary Medicine (GUM) Clinic.

Cervical screening is not a diagnostic tool. Women presenting with symptoms under 25 years of age, please see Clinical Practice Guidance for the Assessment of Young Women aged 20-24 (See Appendix 3).

Q: Women aged 65 and over who have had three consecutive negative samples are taken out of the call/recall system. The natural history and progression of cervical cancer means it is highly unlikely that such women will go on to develop the disease. Women aged 65 and over who have never had a smear are entitled to a test.

Q: What should I do if requested to take a sample from a woman who is under 25 years old and sexually active?

Cytological abnormalities in the cervix, changes to formation, structure & function of the cells are common in women under 25. However these natural & harmless changes can often be identified as cervical abnormalities during screening, which could lead to unnecessary further investigations & treatment. In addition, women in this age group frequently contract the Human Papilloma Virus (HPV) which causes cervical abnormalities. If found at screening these are treated but if left alone they usually resolve spontaneously by the age of 25. Therefore taking a sample from a woman in this age group could do more harm than good.

Q: Should women who are not sexually active still have cervical screening?

Women who have never been sexually active with a man are at a very low (although not zero) risk for developing cervical cancer. In these circumstances, it is usually left up to the woman to decide after providing her with the facts. If the woman is currently not sexually active but has previously been with male partners, then cervical screening is recommended.
Q: What should I advise a lesbian woman who attends for cervical screening and has never had sexual intercourse with a man?

A lesbian woman is entitled to the same cervical screening interval as a heterosexual woman. Sometimes, lesbian women have been advised by health workers that they don’t need screening because they don’t have sex with men. Or, they may be told by other lesbians that they don’t need to be screened. However, women should be offered screening and consider attending, regardless of their sexual orientation. Research suggests that although HPV is more easily transmitted through heterosexual intercourse, it can also be transmitted through lesbian intercourse. As with other sexually transmitted infections, HPV is passed on through body fluids. This means that oral sex, transferring vaginal fluids on hands and fingers, or sharing sex toys, can all be ways of being exposed to HPV.

A leaflet from the NHSCSP for lesbian women can be downloaded from www.cancerscreening.nhs.uk/cervical/lesbian-bisexual.html

The NHSCSP in partnership with The University of Salford funded a twelve month research project (incorporating a nine month awareness raising campaign) targeting lesbian and bisexual women in the North West of England who were less likely to access health care compared to the general population of women. The findings of the project can be found in the link below.

http://www.lgf.org.uk/Our-services/Campaigns/-are-you-ready-for-your-screen-test-summary-report/

Q: What is the likelihood of an abnormal cervical test result?

In 2012/13, of the tests which were adequate 93.4% were reported as negative. Of the abnormal test results, 3.5% were reported as borderline. Only 1.8% were reported as moderate and 0.6% showed severe dyskaryosis.

Q: When is the optimum time to obtain a cervical sample?

Mid cycle is the optimum time to get a good sample. When a woman is menstruating is not the best time to take a sample, but if this is the only opportunity then it can be taken.

Q: Can the Cervex Brush® be used when an extensive ectropion is present?

Yes, anchor the brush in the os, rotate the brush 360° five times in a clockwise direction, then gently retract the brush from the os, maintaining contact with the cervix, use a circular sweeping action to cover the ectropion and rotate the brush again 360° twice in a clockwise direction.

Q: What action should be taken if the cervix appears “abnormal”?

Obtain a second opinion from an experienced colleague. Take the sample if it is due and refer immediately to gynaecology. Do not wait for result of the sample prior to referring.

Q: What happens if you drop the brush before putting it in the vial or if the vial is spilt after placing the brush inside?

Do not discard the brush head. Place the brush head in the vial in the usual way and record the incident on the request form. If the result is abnormal
the case will be reported as such, if it is negative, an inadequate result will be reported with a repeat recommended in 3 months. Each vial has 10mls of the ethanol fixative in it.

Q: What is the significance of endocervical & metaplastic cells?

The presence of either of these cells suggests that the transformation zone (where abnormal cell changes usually occur) has been sampled. This may give some indication of the adequacy of the sample.

In the follow up of women treated for cervical glandular intraepithelial neoplasia (CGIN) the presence of endocervical cells in the sample are mandatory for appropriate sampling.

Q: How are direct referrals for colposcopy being managed?

The sample taker must first obtain consent to take the sample. They will then inform the patient that, if she should require colposcopy, she will be informed of this by letter and then either sent an appointment or asked to telephone the colposcopy clinic to make her own appointment. The cytology laboratory will forward any abnormal results directly to the colposcopy co-ordinator. All results will be copied to the GP.

If the woman does not respond to the appointment, the GP will be informed and the woman may be contacted by the colposcopy clinic.

Q: Does a girl aged 12 years who had the Cervarix vaccine require the Gardasil vaccine?

No she does not. From September 2013, although a different vaccine was used in the HPV vaccination programme, Gardasil, she will not require further vaccinations. Gardasil protects against the two types of HPV virus that cause more than 70 per cent of cervical cancer in England and two types of HPV virus that cause 90 per cent of genital warts. The HPV vaccination programme was implemented in September 2008 following advice from the independent experts on Immunisation. The Joint Committee on Vaccination and Immunisation recommended that the HPV vaccine should be offered routinely to females aged 12 to 13 years, and also offered a catch-up programme for girls up to 18 years of age.

Q: If a woman has undergone gender reassignment and is now registered as a man will he be invited to attend for cervical screening by the PCSA?

When the PCSA is notified that a woman has undergone gender reassignment, steps are taken to amend the registration details on the NHAIS (Exeter) system. It is not necessarily the case that the persons notified have undergone gender reassignment surgery. Once the system has been updated to show the sex as male and the title as Mr, it will not be possible to generate cervical screening letters to the patient and neither would this be appropriate. Prior to recording the necessary changes to the system, PCSA staff should print a copy of the woman’s screening record.

In cases of possible invasion/suspicion of cancer, it is important that patients are seen within the two week guidelines. GPs have the ultimate responsibility to ensure that these patients are seen in colposcopy clinics.
This should then be sent to the GP explaining that the person will no longer be invited to attend for screening by the screening programme and that the GP should arrange any further tests if appropriate. This is obviously a very sensitive area and care should be taken to ensure that such letters are sent to the GP in a sealed envelope marked “strictly private and confidential”.

http://www.neyhqarc.nhs.uk

Q: **What is a trachelectomy?**

For some women with a very early cancer of the cervix, it may be possible to have a trachelectomy. In this type of surgery the cervix and the upper part of the vagina are removed, but the rest of the uterus (womb) is left in place. The lymph glands in the pelvis are also removed. The operation may be done as an open operation or through a combination of keyhole and vaginal surgery.

As the uterus is not removed, a trachelectomy allows for the possibility that the woman could have children. During the operation or during pregnancy, a stitch is made at the bottom of the uterus to keep it closed. There is a significantly higher chance of miscarriage or premature delivery after this procedure and the baby will be delivered early by Caesarean section [1].

Trachelectomy is only suitable for women with early stage cancer of the cervix.

This type of surgery is not common and is only done in Specialist Gynaecological Cancer Centres.

References

Resources

NHSCSP  www.cancerscreening.nhs.uk/cervical
Jo’s Trust  www.jostrust.org.uk
QARC  www.neyhqarc.nhs.uk   Tel: 0113 246 6300
The Lesbian and Gay Foundation  www.lgf.org.uk/screening
HPV Today  www.hpvtoday.com
Cervical Screening Training  www.cancerscreeningtraining.co.uk

Leaflets, posters and publications are obtainable from DoH Publications Order line
tel: 08701 555455 Email: dh@prolog.uk.com or downloadable at www.cancerscreening.nhs.uk


Human Papillomavirus (HPV) and Cervical Cancer – The Facts.  RCN Publication Code 003 083.  www.rcn.org.uk Tel: 01845 7726100


HPV Triage and Test of Cure, Information for Primary Care. NHSCSP 2011
This document is available to download from www.cervicalscreeningtraining.co.uk

For further information please contact:

Cervical Screening Training
New Croft House
Market Street East
Newcastle upon Tyne
NE1 6ND

Email: michelle.harrison5:nhs.net
Tel: 0191 2292950
Fax: 0191 2292977
APPENDICES

**Appendix 1**  Example of letter to give to women (3rd invitation)

**Appendix 2**  Example of letter to give to women following Cervical Screening

**Appendix 3**  Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding

**Appendix 4**  Vault Sample

**Appendix 5**  Example of Practice Protocol for Cervical Screening
Dear

I am writing to remind you that your cervical screening test is overdue. The reason for reminding you is that screening allows us to detect and treat small changes before they develop into cancer. By attending for screening you are significantly reducing your risk of developing cervical cancer.

If there is a reason that you have been put off attending I would be grateful if you could give me a call to discuss it and to allow me to update your medical records.

All the nurses that undertake screening have been trained to a high standard. The equipment we now use is all disposable and the sample which is sent to the Laboratory uses the latest technology. The number of samples which the laboratory are unable to report on has reduced dramatically which means less women will receive an inadequate result requiring a re--test.

The time between having your sample and receiving the result has also greatly improved. All women should now receive their result in writing within 2 weeks.

If you have any concerns around screening please do not hesitate contacting me either by phone or by making an appointment with me. I am available on ............

It is your choice if you do not wish to participate in screening but it is known to save lives.
Thank you for attending for your cervical screening test which was done by
……………………………………… on …………………………………………
• The result will be sent to your home address, and also to the person who has
taken your sample within 2 weeks.
• If the result is negative, which means normal, you will need to have another test
in 3 years if this test was taken before your 50th birthday or in 5 yrs if you are
over 50.
• If the screening result shows mild abnormalities (called borderline or mild
dyskaryosis) an HPV test will be carried out on the sample. If HPV is found in the
sample then you will be invited to go for colposcopy. Colposcopy involves looking
closely at the cervix to see whether any treatment is needed. The laboratory
will refer you to the colposcopy clinic. Only very rarely does this happen, and
you will be contacted by post. It will include an information leaflet explaining
about the clinic and your future care. Please do not ignore this appointment; it
is important that you attend.
• If the screening result shows moderate or severe dyskaryosis you will be referred
to Colposcopy.
• Sometimes, in approximately 1 - 2% of women, the sample is reported as being
unsatisfactory and you will need to come back for this test to be repeated. This
is no indication of an abnormal result.
• If this is your first test after treatment at colposcopy and the result is normal,
borderline or mild the sample will be tested for HPV. If HPV is not found you
will not need to be screened for another three years. If HPV is found, or if the
screening result shows moderate or severe dyskaryosis, you will be invited for
colposcopy again.
• Occasionally a reminder letter is sent by the Screening Office after you have had
your sample taken but before the result is known. Disregard this and wait for
your letter informing you of your result.
• If you have any unusual symptoms, such as bleeding after sex or between your
periods, please make an appointment to see the Doctor or Nurse.
• If you have any questions or concerns between tests please contact
……………………………………….
Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding
Clinical Practice Guidance for the Assessment of Young Women aged 20-24 with Abnormal Vaginal Bleeding

Background

A recent review by the Advisory Committee for Cervical Screening recommended no change to the age of commencing cervical screening and that the screening range would remain at 25-64 years.

This decision was based on the potential for more harm, through morbidity consequent to screening, than benefit achieved by preventing cervical cancer. It was recognised, however, that in the rare cases of cervical cancer which do occur in women younger than 25 years (around 50 per year, with 0-5 deaths). There is a delay in diagnosis in a significant proportion because of delayed pelvic examination following self-referral with abnormal bleeding. The explanation for these delays, which have been documented at 4-6 months in some cases, is that relatively common symptoms of abnormal vaginal bleeding may be attributed initially to dysfunctional bleeding, or related to oral contraceptive use. The ACCS recommended the development of clinical practice guidance, which would reduce the risk of a delayed diagnosis of cervical cancer, by identifying those women most at risk of cervical cancer.

The Size of the Problem

The number of women aged 20-24 years who develop cervical cancer is generally fewer than 50 cases per year and this will fall over the next 10 years as a consequence of the national HPV vaccination programme. By contrast abnormal vaginal bleeding is relatively common in this age group. It has been estimated from a general practice dataset in Scotland (unpublished) that postcoital bleeding is reported by around 1 in 600 women aged 20-24 per year. Intermenstrual bleeding is more common than this and it may be that 0.5-1% of women in this age present with abnormal vaginal bleeding each year. There are around 1.5m women aged 20-24 in England and it could, therefore, be estimated that 7,500 – 15,000 women per year will report abnormal vaginal bleeding. In practice the number could be larger than this.

Developing a Guidance for Clinical Practice

The cardinal symptom of cervical cancer in this age group is postcoital bleeding, but persistent intermenstrual bleeding, which is more common, also requires attention. The critical intervention in the diagnosis of cervical cancer is an immediate speculum examination as recommended by SIGN2 and NICE3 Guidance, to enable a clear view of the cervix. Following a relevant history, it is, therefore, necessary for women who present with postcoital bleeding or persistent intermenstrual bleeding to be offered a speculum examination either in primary care or at a GUM clinic. This could be performed by a practice nurse experienced in cervical screening.

If the cervix looks abnormal and suspicious, which will be the case in a very small proportion, the correct action is urgent referral to colposcopy under the ‘two week wait’ rule. If there is a benign lesion, such as cervical polyp, a routine gynaecological referral will suffice. If the cervix looks normal, the recommended action will be a pregnancy test and testing for cervical infection (e.g. Chlamydia, N Gonorrhoea, Herpes), which could be performed in general practice, family planning clinics or GUM clinics. Any positive tests for sexually transmitted infections would need to be appropriately treated.

iii
This pathway is illustrated below.

The impact of this guidance will be monitored by the Advisory Committee for Cervical Screening.

NHS Cancer Screening Programmes produce Cervix chart for sample takers in primary care, with pictures of the cervix showing various abnormalities. Copies of the chart can be ordered from www.orderline.dh.gov.uk, quoting NHSCSP publication No 25.

References


This guidance was developed by a working Subgroup of the Advisory Committee on Cervical Screening:

HC Kitchener (ACCS Chair)
C Sonnex (ACCS, GUM)
J Butler (DH, Gynaecology)
S Firth (ACCS, GP)
K Moss (ACCS, GP)
M Shafi (ACCS, Gynaecology)
P Walker (Invited member, Gynaecology)
Clinical Practice Guidance for the Assessment of Young Women Aged 20-24 with Abnormal Vaginal Bleeding

**Speculum and Pelvic Examination**

- **History including sexual and contraceptive history & LMP**
- **IMB** – intermenstrual bleeding
- **PCB** – post coital bleeding
- **LMP** – last menstrual period

**Suspected oral contraceptive problem**
- Yes → OCP modification
- No

**Clinical Suspicion of Cervical Cancer**

- Cervical pathology not suggestive of cancer (e.g. polyp, ectropion, cervicitis, warts)
- Normal Cervix
- Swabs for STI or Refer to GU Medicine

**Referral to Gynaecology/GU Medicine (According to local guidance)**
- Persistent Symptoms (6-8 weeks)
- Treat Infection if found

**Fast Track Colposcopy**

- Persistent Bleeding (6-8 weeks)

**Treat Infection if found**

**Treat local cause or**

**Suspected oral contraceptive problem**

**OCP** – oral contraceptive pill

**GU Medicine** – Genitourinary medicine

**STI** – Sexually transmitted medicine

**PCB** – post coital bleeding

**IMB** – intermenstrual bleeding

**LMP** – last menstrual period
VAULT SAMPLE

Women who have had routine recall prior to hysterectomy and NO CIN in their hysterectomy specimen

- Cease recall. Inform Screening Office
- No vault cytology is required

Women not on routine recall and NO CIN in their hysterectomy specimen

- Cease recall. Inform Screening Office
- Vault sample 6 months after surgery at GP’s. If negative no further cytology follow up.

Women with completely excised CIN at hysterectomy

- Cease recall. Inform Screening Office
- Vault sample at 6 and 18 months after surgery at GP’s. If both are negative no further cytology follow-up.

Women with incomplete or uncertain excision of CIN at hysterectomy

- Conduct follow-up as if cervix were still in situ. i.e. low risk (CIN 1) and high risk (CIN 2 or 3)
- Low risk – Vault sample at 6, 12 and 24 months then a routine interval at GP’s. Refer to colposcopy if appropriate
- High risk – Vault sample 6 and 12 months then annual for 9 years. If all negative then at routine interval at GP’s. Refer to colposcopy if appropriate.

Ref: Luesley D & Leeson S. Colposcopy and Programme Management NHSCSP Publication No. 20, second edition 2010
### Example of Practice Protocol for Cervical Screening

<table>
<thead>
<tr>
<th>AIMS</th>
<th>To reduce mortality and morbidity from cervical disease, to work in accordance with the NHS cervical screening programme, and to promote sexual health of the practice population</th>
</tr>
</thead>
</table>
| OBJECTIVE | • to encourage attendance for cervical screening  
• to promote patient understanding and awareness of the procedure and the implications of screening and follow-up  
• to adhere to a systematic call and recall system  
• to promote sexual health opportunistically where appropriate  
• to perform the sample tests effectively and minimise physical and psychological distress |
| CLIENT GROUP – INCLUSION | In accordance with National Guidelines  
• consenting patients between the ages of 25 and 64 with an intact uterus or partial hysterectomy where the cervix has been left in place  
• only screen those who are 65+ who have not been screened since age 50 or have had recent abnormal tests  
• women being followed up for a previous abnormal sample as per local guidelines  
• this includes lesbian and bisexual women (NHSCSP Colposcopy & Programme management Publication No 20 (2010))  
• women who have had a hysterectomy (see vault guidelines for those women who may require vault samples)  
• women under 25 years of age  
• women over 64 years of age who have had 3 consecutive negative samples  
Follow guidelines if ceasing women.  
**NB:** Non-consenting patients or those unable to make an informed choice (learning disabilities) should be treated in accordance with local and national guidelines.  
*(Best Practice Guidance for the Management of Women with a ‘Lack of Capacity’ within the NHSCSP (2009))*. |
### STAFF REQUIREMENTS
- all nurses with a valid NMC registration working within the NMC Code of professional conduct: Standards for conduct, performance and ethics (2008) who hold a recognised cytology course qualification or has had relevant experience.
- attends update training every three years. It is required that in addition the elearning package is also completed.
See [www.cervicalscreeningtraining.co.uk](http://www.cervicalscreeningtraining.co.uk)

### EQUIPMENT
- private lockable room.
- couch.
- moveable strong spot light.
- assorted sizes of single use specula or re-usable specula sterilised to DoH standards.(DoH 2006 The Health Act)
- patient information leaflets.
- swabs.
- gloves - seamless, unpowdered latex or vinyl
- disposable modesty sheet roll.
- single use sachets of water based lubricant.
- LBC sample taker kits and endocervical brushes.
- disposable apron

### CLINICAL ASPECTS

#### ACTION
- act at all times in a manner which maintains the women’s dignity and safety (psychological and physical)
- explain and discuss procedure including rationale, limitations of sample test, abnormal results and follow-up procedure
- adhere to the principles of infection control e.g. handwashing, decontamination of equipment (DoH (2006)The Health Act)
- take a general and sexual health history, including discussing the possibility of an HPV test
- take the sample using the appropriate technique ensuring:
  - full visualisation of cervix
  - sampling of transformation zone in its entirety 360º sweep x 5
  - if procedure unsuccessful refer to appropriate practitioner.

#### RATIONALE
- maintenance of women’s dignity and confidence in the screening programme
- to protect the dignity and rights of the patient, and to protect the healthcare professional from any future accusation of malpractice
- ensure understanding
- gain informed consent
- to protect self and client from contamination
- to determine suitability for screening and contributing factors which may influence the procedure and laboratory screening
- ensure adequate sample to enable efficiency of screening programme
- to obtain adequate sample
<table>
<thead>
<tr>
<th><strong>ADVICE &amp; REFERRAL</strong></th>
<th><strong>RECORD KEEPING</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Post procedure advice:</td>
<td>In accordance with NMC recommendations written and computerised records will be maintained including relevant history and any abnormalities e.g</td>
</tr>
<tr>
<td>• reassure, give appropriate leaflet and information to ensure the woman is fully informed about all aspects of procedure, follow up, including direct referral and how patient will be informed of results</td>
<td>• post coital bleeding or pain</td>
</tr>
<tr>
<td></td>
<td>• inter-menstrual bleeding</td>
</tr>
<tr>
<td></td>
<td>• post menopausal bleeding</td>
</tr>
<tr>
<td></td>
<td>• unusual vaginal discharge</td>
</tr>
<tr>
<td></td>
<td>• appearance of cervix</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>AUDIT</strong></th>
<th><strong>SYSTEMS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• All sample takers should be registered on the CSTD(Cervical Sample Taker database)</td>
<td>• a named individual in each practice is the Sample Taking Coordinator, responsible for overseeing the running of the screening programme</td>
</tr>
<tr>
<td>• All sample takers should audit a random sample of a minimum of 20 consecutive samples annually including the adequacy rate</td>
<td>• That there is a system in place for notifying women of their test results in writing</td>
</tr>
<tr>
<td>• Use individual sample taker code on all requests</td>
<td>• That a register of samples taken is maintained</td>
</tr>
<tr>
<td>• Receive annual individual feedback from laboratory to include Tz sampling rate for women aged 25-50years</td>
<td>• That results are received for samples sent to the laboratory – this can be achieved by using a specific record book or relevant Read codes on the computer</td>
</tr>
<tr>
<td>• Monitor population coverage</td>
<td>• Abnormal results are acted upon appropriately</td>
</tr>
</tbody>
</table>

- ensures responsibility and accountability framework in place
- minimises clinical risk
- enabling monitoring of uptake to meet national targets
- best practice

(NHSCSP Publication 21 2004)
REFERENCES

NHSCSP Publication No 20. Colposcopy and Programme Management

NHSCSP Publication No 21. Guidelines for Failsafe Actions for the follow-up of Cervical Cytology Reports

NHSCSP Good Practice Guide No 1. Ceasing women from the NHS Cervical Screening Programme. Feb 2004

NHS Cancer Screening Series No 2. Equal access to Breast and Cervical Screening for Disabled women

NHS Cancer Screening Series No 4. Consent to Cancer Screening

NMC The Code - Standards of conduct, performance, and ethics for nurses and midwives 05.2010

NMC Guidelines for Records and Record Keeping 2010

Chaperoning NMC 2010

www.rcn.org.uk/mrsa

The Health Act 2006: Code of Practice for the Prevention and Control of Healthcare Associated Infections
